In what was a fait accompli after a failed outcomes study for Merck's (MRK +3.48%) cholesterol drug Tredaptive, the big pharma giant just announced it was suspending sales of the drug. Motley Fool health-care analyst David Williamson explains the embarrassing situation and what this means for investors.
